RTP Mobile Logo

The treatment of Hodgkin and non-Hodgkin lymphoma remains a challenge for many healthcare professionals. However, recent clinical research gains have made an abundance of treatment options available to patients with these hematologic cancers. Furthermore, published results from ongoing clinical trials continually lead to the emergence of new therapeutic regimens and changes in the use of existing treatments. To provide oncology nurses with knowledge, information and strategies they can use to address the disparate needs of patients, the Oncology Nursing Update audio series employs one-on-one interviews with medical oncologists and nurses who are experts in these diseases. As a result, upon completion of this CNE activity, oncology nurses should be able to better counsel and educate patients while developing up-to-date approaches for the management of Hodgkin and non-Hodgkin lymphoma.

To present the most current research developments in Hodgkin and non-Hodgkin lymphoma and to provide the perspectives of nurse practitioners and clinical investigators on the diagnosis and treatment of these diseases.


  • Appraise the recent FDA approvals of ibrutinib, idelalisib and obinutuzumab, and discern how these agents can be appropriately integrated into clinical practice for patients with chronic lymphocytic leukemia and other B-cell neoplasms.
  • Discuss the risks and benefits associated with novel agents and combination regimens under evaluation for indolent and aggressive B-cell and T-cell non-Hodgkin lymphomas.
  • Develop a plan to manage the side effects associated with commonly used systemic therapies to support quality of life and continuation of treatment.
  • Evaluate the efficacy and safety of brentuximab vedotin for patients with CD30-positive lymphomas, and integrate this information into patient care.
  • Identify opportunities to enhance the collaborative role of oncology nurses in the comprehensive biopsychosocial care of patients with Hodgkin and non-Hodgkin lymphomas.


CME credit is no longer available for this issue


CME credit is no longer available for this issue

ONCC/ILNA Certification

CME credit is no longer available for this issue

This is an audio program. Participants should read the learning objectives and faculty disclosures and listen to the MP3s.

CME credit is no longer available for this issue

Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CNE activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Ms MoranAdvisory Committee: Genentech BioOncology. Dr EvensAdvisory Committee and Consulting Agreements: Celgene Corporation, Genentech BioOncology, Takeda Oncology; Contracted Research: Takeda Oncology; Speakers Bureau: Celgene Corporation. Dr SmithAdvisory Committee: Celgene Corporation, Pharmacyclics Inc, Seattle Genetics, TG Therapeutics Inc; Consulting Agreement: Celgene Corporation; Data and Safety Monitoring Board: Genentech BioOncology; Speakers Bureau: Janssen Biotech Inc. Ms RogersAdvisory Committee: Gilead Sciences Inc, Takeda Oncology; Speakers Bureau: Seattle Genetics, Takeda Oncology.

EDITORDr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME/CNE activities from the following commercial interests: AbbVie Inc, Amgen Inc, Astellas Scientific and Medical Affairs Inc, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Biodesix Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Incyte Corporation, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Lilly, Medivation Inc, Merck, Myriad Genetic Laboratories Inc, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Teva Oncology, Tokai Pharmaceuticals Inc and VisionGate Inc.

RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

This activity is supported by educational grants from Celgene Corporation and Gilead Sciences Inc.

Hardware/Software Requirements:
A high-speed Internet connection
A monitor set to 1280 x 1024 pixels or more
Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
Adobe Flash Player 10.2 plug-in or later
Adobe Acrobat Reader
(Optional) Sound card and speakers for audio

Last review date: June 2015
Expiration date: June 2016

There is no implied or real endorsement of any product by RTP or the American Nurses Credentialing Center.